Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIDSTORM (tocilizumab in hospitalized COVID-19)
2020-002039-31Phase 3Terminated
- Sponsor
- Turku University Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing RoActemra arm with Standard of care arm (2 arms). Primary endpoint: Clinical status at day 28. Started Apr 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002039-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002039-31.